- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00378469
Study of the Effects of Muscular Activity on Iron Metabolism
Study of the Effects of Muscular Activity on Iron Metabolism: A Pilot Study on Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hemojuvelin has been described as interfering with hepcidin, a key regulator of iron homeostasis. Hemojuvelin is mainly produced by muscle, and the relationship between exercise and iron metabolism can be questioned about.
The aim of this study is to evaluate the effect of muscular exercise on iron metabolism in healthy volunteers. Fourteen healthy male subjects will be investigated at two periods according to a cross-over design after:
- 45 minutes of exercise on the ergocycle; and
- no physical exercise.
Urine and blood samples will be collected at both periods regularly to measure hemojuvelin, hepcidin, iron and transferrin levels.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Pierre Brissot, MD
- Phone Number: 33-2-9928-4297
- Email: pierre.brissot@univ-rennes1.fr
Study Contact Backup
- Name: Fabrice Lainé, MD
- Phone Number: 33-2-9928-3715
- Email: fabrice.laine@chu-rennes.fr
Study Locations
-
-
-
Rennes, France, 35033
- Recruiting
- Service des Maladies du Foie - Hôpital de Pontchaillou
-
Sub-Investigator:
- Fabrice LAINE, MD
-
Contact:
- Pierre Brissot, MD
- Phone Number: 33-2-9928-4297
- Email: pierre.brissot@univ-rennes1.fr
-
Principal Investigator:
- Pierre Brissot, MD
-
Sub-Investigator:
- Yves Deugnier, MD
-
Rennes, France, 35033
- Recruiting
- Unité de Biologie et Médecine du Sport - Hôpital de Pontchaillou
-
Contact:
- Pierre Rochcongar, MD
- Phone Number: 33-2-9928-9323
- Email: pierre.rochcongar@chu-rennes.fr
-
Principal Investigator:
- Pierre Rochcongar, MD
-
Sub-Investigator:
- Jocelyne Beillot, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male individuals aged between 18 and 40 years old
- Body mass index (BMI) between 18 and 25
- Normal at clinical examination
- Normal biological variables
- Written informed consent
Exclusion Criteria:
- Mutation C282Y of the HFE gene
- Iron metabolism abnormality
- Inflammatory syndrome
- Chronic pathology or ongoing treatment
- Tobacco smoking, alcohol consuming more than 30g/day
- History of transfusion or blood-giving within 3 months
- Positive serology for hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Pharmacokinetics of urinary hepcidin
|
Pharmacokinetics of blood hemojuvelin
|
Secondary Outcome Measures
Outcome Measure |
---|
Pharmacokinetics of urine and blood iron, transferrin, interleukin-6 (IL-6) and ferritin
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Bruno Laviolle, MD, Rennes University Hospital
- Principal Investigator: Pierre Brissot, MD, Rennes University Hospital
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DGS 2006/0415
- LOC/05-07
- CIC0203/061
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron Overload
-
Novartis PharmaceuticalsCompletedTransfusional Iron OverloadItaly
-
ApoPharmaCompletedTransfusional Iron OverloadEgypt, Cyprus, Oman, Saudi Arabia, Turkey
-
Novartis PharmaceuticalsCompletedChronic Iron OverloadGermany
-
Novartis PharmaceuticalsCompletedCardiac Iron OverloadTaiwan, Egypt, Thailand, Turkey, United Kingdom, Italy, Canada, Greece
-
Novartis PharmaceuticalsNot yet recruiting
-
Assiut UniversityUnknownPlatelet Changes in Cases of Iron Overload
-
ApoPharmaCompletedIron Overload Due to Repeated Red Blood Cell TransfusionsUnited States, Canada, Greece, Italy
-
Assiut UniversityUnknownPlatelet Changes in Cases of Iron Overload
-
ShireTerminatedIron Overload Due to Repeated Red Blood Cell TransfusionsCanada, United States, Thailand, Italy, United Kingdom
-
Rennes University HospitalCompleted
Clinical Trials on 45 minute exercise on ergocycle
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingFibrotic Interstitial Lungs DiseasesFrance
-
University of the French West Indies and French...Institut National de la Santé Et de la Recherche Médicale, FranceCompletedEnvironmental Exposure | Sickle Cell Trait | Adverse EffectGuadeloupe
-
Oklahoma State UniversityRecruitingObesity | Normal-weight ObesityUnited States
-
Medical University of GrazKristiania University CollegeRecruitingPhysical Activity | Cardiometabolic HealthAustria
-
Izmir Dr Suat Seren Chest Diseases and Surgery...Not yet recruitingChronic Obstructive Pulmonary DiseaseTurkey
-
Western University, CanadaUnknownMental Fatigue | Ketosis | KetonemiaCanada
-
Memorial Sloan Kettering Cancer CenterWeill Medical College of Cornell UniversityActive, not recruitingLymphoma | Gynecologic Cancer | Metastatic Cancer | Thoracic Cancer | Genitourinary Cancer | Locally Advanced CancerUnited States
-
Institut de Recherches Cliniques de MontrealSociété Francophone du DiabèteCompleted
-
Universidade Federal de Sao CarlosConselho Nacional de Desenvolvimento Científico e TecnológicoCompletedChronic Obstructive Pulmonary DiseaseBrazil
-
Texas Woman's UniversityNot yet recruitingDiabetes ComplicationsUnited States